On Behalf of BioRestorative Therapies Inc. Hey there,
In the early 2010s, stem cells were the biotech frontier. But most of those companies collapsed — the science wasn’t ready.
Except one.
This US biotech didn’t just survive — it spent over a decade refining a therapy that could solve one of America’s most expensive medical crises: chronic back pain.
The solution? A single, in-office injection using the patient’s own stem cells — no surgery, no donor tissue, and no immune rejection risk.
Early data from its pivotal Phase 2 trial is showing major improvements in pain and function for almost 70% of patients… and the FDA just granted it Fast Track Designation.
Yet the stock trades under $2 — with a market cap under $15M.
That’s right: while its billion-dollar competitor struggles with FDA rejection and outdated donor cells, this company holds a cleaner, safer, and more personalized edge.
The opportunity here is real — and radically underpriced. 👉 Unlock the name and symbol right now
Examples that we provide of share price increases pertaining to a particular Issuer from one referenced date to another represent an arbitrarily chosen time period and are no indication whatsoever of future stock prices for that Issuer and are of no predictive value. Our stock profiles are intended to highlight certain companies for YOUR further investigation; they are NOT stock recommendations or constitute an offer or sale of the referenced securities.
This message is a paid advertisement for BioRestorative Therapies Inc. (BRTX ) from Market Jar Media Inc. Wealthpire, Inc. has received a fixed fee of $2,500 from BioRestorative Therapies Inc. (BRTX ) for multiple Dedicated Email Sends, and Newsletter Sponsorships. Other than the compensation received for this advertisement sent to subscribers, Wealthpire, Inc. and its principals are not affiliated with either BioRestorative Therapies Inc. (BRTX ) or Market Jar Media Inc. Wealthpire, Inc. and its principals do not own any of the stocks mentioned in this email or in the article that this email links to. Neither Wealthpire, Inc. nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Wealthpire, Inc. to buy or sell any security. Wealthpire, Inc. has not evaluated the accuracy of any claims made in this advertisement. Wealthpire, Inc. recommends that investors do their own independent research and consult with a qualified investment professional before buying or selling any security. Investing is inherently risky. Past-performance is not indicative of future results. Please see the disclaimer regarding BioRestorative Therapies Inc. (BRTX ) on Market Jar Media Inc. website for additional information about the relationship between Market Jar Media Inc. and BioRestorative Therapies Inc. (BRTX ). |